Loading
OmicXHealth
OmicXHealth is a California company developing OmicXScreen, a blood test that uses whole-genome sequencing and machine learning to look for early liver cancer and, later, other cancers.
Also called: OMICXHEALTH, INC.OmicXHealth Inc
Overview
OmicXHealth Inc., of San Ramon, California, develops OmicXScreen, an AI and genomics platform for a blood test for early cancer detection that sequences the whole genome once and performs the analysis in software. The company reports preclinical validation in liver cancer (hepatocellular carcinoma), a completed lung cancer classifier and a proof of concept across six cancer types as part of a multi-cancer early detection roadmap. In fiscal year 2026 the National Cancer Institute funded its SBIR project on OmicXScreen, a DNA methylation profiling test for early hepatocellular carcinoma and oesophageal cancer detection (1R43CA310377-01A1, USD 405,305); the company says the grant funds a blinded validation study for early liver cancer detection at UT Southwestern.
Headquarters
San Ramon, CA, US
Scorecard
All companies#786of 1706 companies, score 2
- modalities +2
0 approved, 0 in phase 3, 0 earlier, 0 targets, 0 registry studies. Formula on the scorecards page.
Funding
All startupsStartup
Investors not recorded; see the round sources.
Rounds on record
| Round | Year | Amount | Source |
|---|---|---|---|
| Grant · NCI SBIR Phase I (R43) award 1R43CA310377-01A1: OmicXScreen: AI/ML-Powered, DNA Methylation Profiling Test for Early HCC and Esophageal Cancer Detection | 2026 | $405K | reporter.nih.gov |
Amounts only where the cited source states them. Rounds without a public source are not listed.
Type
Stage
Startup
Website
Products
1EmergingBlood test (whole-genome sequencing with DNA methylation analysis and machine learning)
OmicXScreen is an investigational blood test from OmicXHealth that reads DNA patterns to look for early liver cancer, with other cancers in development.
Notes
- Read on omicxhealth.com and the NIH RePORTER record on 4 November 2026. Validation statements are the company's own.
Connected
7Similar pages
- Key paperEpiPanGI Dx: A Cell-free DNA Methylation Fingerprint for the Early Detection of Gastrointestinal Cancers
Shares Cell-free DNA methylation tests, Multi-cancer early detection (MCED), Oesophageal cancer, Hepatocellular carcinoma.
- TestEpiPanGI Dx
Shares Cell-free DNA methylation tests, Multi-cancer early detection (MCED), Oesophageal cancer, Hepatocellular carcinoma.
- CompanyAnchorDx
Shares Cell-free DNA methylation tests, Multi-cancer early detection (MCED).
- TestAurora (AnchorDx)
Shares Cell-free DNA methylation tests, Multi-cancer early detection (MCED).
- TestCancerFind
Shares Cell-free DNA methylation tests, Multi-cancer early detection (MCED).
- TrialDECIPHER-GASTRO (liquid biopsy for oesophageal, gastric and colorectal cancer, Shandong)
Shares Multi-cancer early detection (MCED), Oesophageal cancer.
- TestHIFI Pan-Cancer Screening (Berry Oncology)
Shares Multi-cancer early detection (MCED), Oesophageal cancer, Hepatocellular carcinoma.
- TestPanSeer
Shares Cell-free DNA methylation tests, Multi-cancer early detection (MCED), Oesophageal cancer, Hepatocellular carcinoma.
cancers
fronts
technologies
Tests
EmergingBlood test (whole-genome sequencing with DNA methylation analysis and machine learning)
Sources
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
nih.gov · 1
omicxhealth.com · 1
A source that has moved or gone is reported by the weekly link check. /audit/